Inhibitor Therapeutics, Inc. 8-K

What Happened
Inhibitor Therapeutics, Inc. announced on Form 8‑K (filed Feb 24, 2026) that it entered into a Securities Purchase Agreement on February 19, 2026 with an institutional investor to raise $3,000,000. Under the agreement the company agreed to sell 12,000,000 shares of common stock at $0.25 per share and to issue a warrant to purchase up to 7,000,000 additional shares. As of the filing date the Financing had not yet closed or been funded; the company expects to close within a reasonable period.

Key Details

• Agreed financing: $3,000,000 in exchange for 12,000,000 common shares ($0.25/share) plus a warrant.
• Warrant terms: exercisable for 3 years at $0.35 per share for up to 7,000,000 shares (would generate up to $2,450,000 if fully exercised).
• Transfer and lock-up: shares issued in the Financing and shares underlying the warrant are subject to Securities Act transfer restrictions; investor agreed not to sell those shares until the earlier of nine months after the SPA date or a Change in Control.
• Use of proceeds: planned for working capital and general corporate purposes. Financing not yet closed/funded as of Feb 24, 2026.

Why It Matters
This transaction would provide immediate cash (if closed) to support Inhibitor Therapeutics’ operations and extend its financial resources. The financing also creates potential future capital if the warrants are exercised (up to an additional $2.45M). Investors should note the potential dilution from the 12,000,000 issued shares plus up to 7,000,000 shares if warrants are exercised, and that resale of the financed shares is restricted for a defined period. Finally, the agreement remains subject to closing, so the financing is not yet finalized.